Gastric gastrointestinal stromal tumors. Is there a necessity to use imatinib in the intermediate-risk group?
| Autor: | O., Yalav1, S., Gumus2, M. O., Gul2 mehmetonurgul@hotmail.com, I. C., Eray1, A., Rencuzogullari1 |
|---|---|
| Zdroj: | Hippokratia. 2021, Vol. 25 Issue 3, p113-118. 6p. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|